• Reliable Gene Editing with EZ Cap™ Cre mRNA (m1Ψ): Lab Scena

  2026-06-19

  This article delivers a scenario-driven examination of common laboratory challenges in Cre-lox gene editing, focusing on how EZ Cap™ Cre mRNA (m1Ψ) (SKU R1030) from APExBIO addresses workflow reproducibility, translation efficiency, and low immunogenicity. Researchers will find actionable guidance and validated parameters for optimizing cell-based assays using advanced mRNA technology.

• PXR Activation Enhances Urine Concentration via AVP Upregula

  2026-06-18

  This study demonstrates that activation of the pregnane X receptor (PXR) in the hypothalamus increases urine concentration by upregulating arginine vasopressin (AVP) expression. These findings reveal a novel neuroendocrine function for PXR, with potential implications for water homeostasis disorders.

• Applied Workflows with Verteporfin: Precision in CL 318952 A

  2026-06-18

  Verteporfin, supplied by APExBIO, is transforming photodynamic therapy and autophagy research with its dual-action profile. This guide demystifies practical protocols, highlights troubleshooting strategies, and bridges recent mechanobiology insights for next-generation cell viability and apoptosis assays.

• MLN4924 HCl Salt in Host-Pathogen Dynamics: Beyond Cancer Re

  2026-06-17

  Explore how MLN4924 HCl salt, a NEDD8-activating enzyme inhibitor, advances research on protein turnover in viral immunity and inflammation. This article uniquely bridges cancer biology and host-pathogen interaction studies.

• Phosphatase Inhibitor Cocktail 1: Precision in Phosphoproteo

  2026-06-17

  Phosphatase Inhibitor Cocktail 1 (100X in DMSO) empowers researchers to preserve phosphorylation states with exceptional fidelity, even in challenging workflows like signaling pathway dissection and viral infection models. This guide details advanced use-cases, troubleshooting, and cutting-edge protocol enhancements, providing an actionable resource for maximizing reproducibility in phosphoproteomics.

• Intravesical p21 mRNA-LNP Therapy for Bladder Cancer: Advanc

  2026-06-16

  This study presents a non-viral, intravesical delivery of p21 mRNA-loaded lipid nanoparticles as a tumor suppressor replacement strategy for bladder cancer. The approach demonstrates robust antitumor efficacy with minimal systemic exposure, suggesting a promising direction for localized mRNA therapies in non-hepatic solid tumors.

• RSAD2 Drives Placental Lipid Accumulation in SLE Pregnancies

  2026-06-16

  Ding et al. identify RSAD2 as a pathogenic interferon-stimulated gene at the maternal-fetal interface in systemic lupus erythematosus (SLE) pregnancies. Their work demonstrates that RSAD2 excess impairs placental vasculogenesis through lipid accumulation, and that targeted inhibition of RSAD2 can alleviate vascular inflammation, highlighting a novel pathway for intervention in SLE-associated pregnancy complications.

• DMH1: Precision ALK2 Inhibitor for Organoid and NSCLC Resear

  2026-06-15

  DMH1 stands out as a selective ALK2 inhibitor enabling fine-tuned BMP pathway modulation for both organoid engineering and non-small cell lung cancer research. Its robust specificity and protocol-ready formulation empower reproducible control over stem cell fate and tumor suppression.

• G-1 (CAS 881639-98-1): Scenario-Guided Use in GPR30 Research

  2026-06-15

  This article delivers practical, scenario-driven strategies for reliable GPR30 activation in cell viability, proliferation, and cytotoxicity assays using G-1 (CAS 881639-98-1), a selective GPR30 agonist (SKU B5455). Drawing on validated protocols and recent literature, we address real laboratory challenges and workflow optimizations for biomedical researchers. Evidence-based recommendations highlight G-1’s specificity and reproducibility advantages.

• LMO2–LDB1 Complex Drives AML Progression: Mechanistic Insigh

  2026-06-14

  This study reveals that the LMO2/LDB1 protein complex plays a central role in acute myeloid leukemia (AML) progression by promoting leukemic cell proliferation and survival. The findings highlight the mechanistic significance of this interaction and open avenues for targeted therapeutic strategies.

• Apicidin: Histone Deacetylase Inhibitor in Cancer and Oocyte

  2026-06-13

  Apicidin stands out as a selective histone deacetylase inhibitor with dual utility: from probing anti-proliferative pathways in cancer models to revealing epigenetic disruption in oocyte maturation. This article translates the latest mechanistic findings and protocol optimizations into actionable guidance for advanced experimental workflows.

• Carvedilol: Strategic Advances in β-Adrenergic Receptor Rese

  2026-06-12

  This thought-leadership article explores how Carvedilol, a dual β- and α1-adrenergic receptor antagonist, is transforming translational research across cardiovascular and hematopoietic domains. We synthesize mechanistic insights, emerging evidence, and practical workflow guidance to help researchers navigate evolving model systems and clinical translation. By critically engaging with recent breakthroughs—especially in hematopoietic regeneration—we chart a course for rigorous, reproducible, and impactful studies.

• Dlin-MC3-DMA: Ionizable Cationic Liposome for RNA Delivery

  2026-06-12

  Dlin-MC3-DMA redefines RNA delivery with its ionizable cationic liposome structure, enabling ultra-efficient siRNA and mRNA transport for gene silencing and vaccine workflows. This article translates the latest machine learning-validated innovations and real-world troubleshooting insights into actionable steps for robust, reproducible results.

• Systematic Assessment of Leucomycin Antibacterial Activity I

  2026-06-11

  Iwata and Akiba's foundational study delineated the in vitro antibacterial spectrum and potency of leucomycin (kitasamycin) and its A1 fraction, benchmarking their activity against erythromycin, oleandomycin, and standard drugs. Their work provided early, systematic evidence of leucomycin's efficacy against clinically relevant and resistant bacterial strains, informing both translational inhibition research and resistance mechanism studies.

• I-BET-762: Precision BET Inhibitor for Inflammation & Cancer

  2026-06-11

  I-BET-762 is a highly selective BET inhibitor with nanomolar potency and verified anti-inflammatory and anticancer utility. Recent evidence demonstrates I-BET-762 enhances ferroptosis and modulates transcriptional regulation in preclinical models. Its well-characterized profile supports robust, reproducible workflows in epigenetics and inflammation research.

10313 records 1/688 page Next 12345 下5页 Last page